Obesity - Pipeline Review, H2 2017

Date: November 21, 2017
Pages: 518
Price:
US$ 2,500.00
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: O5F2BC0D9C1EN
Leaflet:

Download PDF Leaflet

Obesity - Pipeline Review, H2 2017
Obesity - Pipeline Review, H2 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Obesity - Pipeline Review, H2 2017, provides an overview of the Obesity (Metabolic Disorders) pipeline landscape.

Obesity is defined as having an excessive amount of body fat. Obesity increases risk of diseases and health problems such as heart disease, diabetes and high blood pressure. The predisposing factors include age, family history, quitting smoking, lack of sleep and certain medications. Treatment includes healthy lifestyle, medications and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Obesity - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Obesity (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Obesity (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Obesity and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 4, 16, 28, 125 and 27 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 57 and 13 molecules, respectively.

Obesity (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Obesity (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Obesity (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Obesity (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Obesity (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Obesity (Metabolic Disorders)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Obesity (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Obesity (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Obesity - Overview
Obesity - Therapeutics Development
Obesity - Therapeutics Assessment
Obesity - Companies Involved in Therapeutics Development
Obesity - Drug Profiles
Obesity - Dormant Projects
Obesity - Discontinued Products
Obesity - Product Development Milestones
Appendix

LIST OF TABLES

Number of Products under Development for Obesity, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Products under Development by Companies, H2 2017 (Contd..7), H2 2017
Products under Development by Companies, H2 2017 (Contd..8), H2 2017
Products under Development by Companies, H2 2017 (Contd..9), H2 2017
Products under Development by Companies, H2 2017 (Contd..10), H2 2017
Products under Development by Universities/Institutes, H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017
Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Obesity - Pipeline by Abeome Corp, H2 2017
Obesity - Pipeline by Adamas Pharmaceuticals Inc, H2 2017
Obesity - Pipeline by Aegis Therapeutics LLC, H2 2017
Obesity - Pipeline by Akron Molecules AG, H2 2017
Obesity - Pipeline by Amgen Inc, H2 2017
Obesity - Pipeline by Antag Therapeutics ApS, H2 2017
Obesity - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2017
Obesity - Pipeline by Arrowhead Pharmaceuticals Inc, H2 2017
Obesity - Pipeline by AstraZeneca Plc, H2 2017
Obesity - Pipeline by Athersys Inc, H2 2017
Obesity - Pipeline by Biophytis SAS, H2 2017
Obesity - Pipeline by BioRestorative Therapies Inc, H2 2017
Obesity - Pipeline by Biozeus, H2 2017
Obesity - Pipeline by Boehringer Ingelheim GmbH, H2 2017
Obesity - Pipeline by Braasch Biotech LLC, H2 2017
Obesity - Pipeline by C3J Therapeutics Inc, H2 2017
Obesity - Pipeline by Callitas Therapeutics Inc, H2 2017
Obesity - Pipeline by Carmot Therapeutics Inc, H2 2017
Obesity - Pipeline by Cereno Scientific AB, H2 2017
Obesity - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2017
Obesity - Pipeline by CohBar Inc, H2 2017
Obesity - Pipeline by CoMentis Inc, H2 2017
Obesity - Pipeline by Connexios Life Sciences Pvt Ltd, H2 2017
Obesity - Pipeline by ConSynance Therapeutics Inc, H2 2017
Obesity - Pipeline by Corcept Therapeutics Inc, H2 2017
Obesity - Pipeline by Daiichi Sankyo Co Ltd, H2 2017
Obesity - Pipeline by DiscoveryBiomed Inc, H2 2017
Obesity - Pipeline by Eisai Co Ltd, H2 2017
Obesity - Pipeline by Eli Lilly and Co, H2 2017
Obesity - Pipeline by Eternygen GmbH, H2 2017
Obesity - Pipeline by Evotec AG, H2 2017
Obesity - Pipeline by FibroGen Inc, H2 2017
Obesity - Pipeline by Genmedica Therapeutics SL, H2 2017
Obesity - Pipeline by Gila Therapeutics Inc, H2 2017
Obesity - Pipeline by Gilead Sciences Inc, H2 2017
Obesity - Pipeline by GlaxoSmithKline Plc, H2 2017
Obesity - Pipeline by Glucox Biotech AB, H2 2017
Obesity - Pipeline by HanAll Biopharma Co Ltd, H2 2017
Obesity - Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017
Obesity - Pipeline by Hyundai Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by Immungenetics AG, H2 2017
Obesity - Pipeline by Intarcia Therapeutics Inc, H2 2017
Obesity - Pipeline by Ionis Pharmaceuticals Inc, H2 2017
Obesity - Pipeline by Ixchel Pharma LLC, H2 2017
Obesity - Pipeline by Johnson & Johnson, H2 2017
Obesity - Pipeline by Juno Therapeutics Inc, H2 2017
Obesity - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by Laboratorios Silanes SA de CV, H2 2017
Obesity - Pipeline by Lead Discovery Center GmbH, H2 2017
Obesity - Pipeline by Leading BioSciences Inc, H2 2017
Obesity - Pipeline by Lotus Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by Magnus Life Ltd, H2 2017
Obesity - Pipeline by MedImmune LLC, H2 2017
Obesity - Pipeline by Merck & Co Inc, H2 2017
Obesity - Pipeline by Naia Ltd, H2 2017
Obesity - Pipeline by NeuroNano Pharma Inc, H2 2017
Obesity - Pipeline by NGM Biopharmaceuticals Inc, H2 2017
Obesity - Pipeline by NIBEC, H2 2017
Obesity - Pipeline by Nordic Bioscience A/S, H2 2017
Obesity - Pipeline by Novartis AG, H2 2017
Obesity - Pipeline by Novo Nordisk AS, H2 2017
Obesity - Pipeline by ObeTherapy Biotechnology, H2 2017
Obesity - Pipeline by Omeros Corp, H2 2017
Obesity - Pipeline by OPKO Biologics Ltd, H2 2017
Obesity - Pipeline by OPKO Health Inc, H2 2017
Obesity - Pipeline by Oramed Pharmaceuticals Inc, H2 2017
Obesity - Pipeline by Orexigen Therapeutics Inc, H2 2017
Obesity - Pipeline by Palatin Technologies Inc, H2 2017
Obesity - Pipeline by Pfizer Inc, H2 2017
Obesity - Pipeline by PharmaIN Corp, H2 2017
Obesity - Pipeline by Poxel SA, H2 2017
Obesity - Pipeline by Prometheon Pharma LLC, H2 2017
Obesity - Pipeline by ReCyte Therapeutics Inc, H2 2017
Obesity - Pipeline by Renova Therapeutics Inc, H2 2017
Obesity - Pipeline by Reviva Pharmaceuticals Inc, H2 2017
Obesity - Pipeline by Saniona AB, H2 2017
Obesity - Pipeline by Sanofi, H2 2017
Obesity - Pipeline by Seres Therapeutics Inc, H2 2017
Obesity - Pipeline by Shionogi & Co Ltd, H2 2017
Obesity - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by Sorrento Therapeutics Inc, H2 2017
Obesity - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by Toray Industries Inc, H2 2017
Obesity - Pipeline by Vicore Pharma AB, H2 2017
Obesity - Pipeline by Viking Therapeutics Inc, H2 2017
Obesity - Pipeline by Vivus Inc, H2 2017
Obesity - Pipeline by WhanIn Pharmaceutical Co Ltd, H2 2017
Obesity - Pipeline by XL-protein GmbH, H2 2017
Obesity - Pipeline by Yuyu Pharma Inc, H2 2017
Obesity - Pipeline by Zafgen Inc, H2 2017
Obesity - Pipeline by Zealand Pharma AS, H2 2017
Obesity - Dormant Projects, H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..1), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..2), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..3), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..4), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..5), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..6), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..7), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..8), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..9), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..10), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..11), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..12), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..13), H2 2017
Obesity - Dormant Projects, H2 2017 (Contd..14), H2 2017
Obesity - Discontinued Products, H2 2017
Obesity - Discontinued Products, H2 2017 (Contd..1), H2 2017
Obesity - Discontinued Products, H2 2017 (Contd..2), H2 2017
Obesity - Discontinued Products, H2 2017 (Contd..3), H2 2017


LIST OF FIGURES

Number of Products under Development for Obesity, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

COMPANIES MENTIONED

Abeome Corp
Adamas Pharmaceuticals Inc
Aegis Therapeutics LLC
Akron Molecules AG
Amgen Inc
Antag Therapeutics ApS
Aoxing Pharmaceutical Company Inc
Arrowhead Pharmaceuticals Inc
AstraZeneca Plc
Athersys Inc
Biophytis SAS
BioRestorative Therapies Inc
Biozeus
Boehringer Ingelheim GmbH
Braasch Biotech LLC
C3J Therapeutics Inc
Callitas Therapeutics Inc
Carmot Therapeutics Inc
Cereno Scientific AB
Chong Kun Dang Pharmaceutical Corp
CohBar Inc
CoMentis Inc
Connexios Life Sciences Pvt Ltd
ConSynance Therapeutics Inc
Corcept Therapeutics Inc
Daiichi Sankyo Co Ltd
DiscoveryBiomed Inc
Eisai Co Ltd
Eli Lilly and Co
Eternygen GmbH
Evotec AG
FibroGen Inc
Genmedica Therapeutics SL
Gila Therapeutics Inc
Gilead Sciences Inc
GlaxoSmithKline Plc
Glucox Biotech AB
HanAll Biopharma Co Ltd
Hanmi Pharmaceuticals Co Ltd
Hyundai Pharmaceutical Co Ltd
Immungenetics AG
Intarcia Therapeutics Inc
Ionis Pharmaceuticals Inc
Ixchel Pharma LLC
Johnson & Johnson
Juno Therapeutics Inc
Kissei Pharmaceutical Co Ltd
Laboratorios Silanes SA de CV
Lead Discovery Center GmbH
Leading BioSciences Inc
Lotus Pharmaceutical Co Ltd
Magnus Life Ltd
MedImmune LLC
Merck & Co Inc
Naia Ltd
NeuroNano Pharma Inc
NGM Biopharmaceuticals Inc
NIBEC
Nordic Bioscience A/S
Novartis AG
Novo Nordisk AS
ObeTherapy Biotechnology
Omeros Corp
OPKO Biologics Ltd
OPKO Health Inc
Oramed Pharmaceuticals Inc
Orexigen Therapeutics Inc
Palatin Technologies Inc
Pfizer Inc
PharmaIN Corp
Poxel SA
Prometheon Pharma LLC
ReCyte Therapeutics Inc
Renova Therapeutics Inc
Reviva Pharmaceuticals Inc
Saniona AB
Sanofi
Seres Therapeutics Inc
Shionogi & Co Ltd
Sinil Pharmaceutical Co Ltd
Sorrento Therapeutics Inc
Takeda Pharmaceutical Co Ltd
Toray Industries Inc
Vicore Pharma AB
Viking Therapeutics Inc
Vivus Inc
WhanIn Pharmaceutical Co Ltd
XL-protein GmbH
Yuyu Pharma Inc
Zafgen Inc
Zealand Pharma AS
Skip to top


Abdominal Obesity - Pipeline Review, H1 2015 US$ 2,000.00 Jun, 2015 · 55 pages
Seek - Product Pipeline Review - 2014 US$ 1,500.00 Oct, 2014 · 42 pages
Galenea Corp. - Product Pipeline Review - 2015 US$ 1,500.00 May, 2015 · 21 pages

Ask Your Question

Obesity - Pipeline Review, H2 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: